Xiamen Amoytop Biotech Co Ltd (688278) — Working Capital to Net Assets Ratio
Xiamen Amoytop Biotech Co Ltd (688278) has a Working Capital to Net Assets ratio of 54.8% as of June 2025. Working capital of CN¥1.51 Billion (current assets of CN¥1.87 Billion minus current liabilities of CN¥359.79 Million) is measured against net assets of CN¥2.76 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See defensive interval ratio of Xiamen Amoytop Biotech Co Ltd to measure how many days the company can operate on defensive assets alone.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Xiamen Amoytop Biotech Co Ltd Working Capital to Net Assets (2016–2024)
This chart shows how Xiamen Amoytop Biotech Co Ltd's Working Capital to Net Assets ratio has evolved across 9 annual periods from 2016 to 2024. As of June 2025, the ratio stands at 54.8%, reflecting working capital of CN¥1.51 Billion against net assets of CN¥2.76 Billion CNY. For the complete balance sheet picture, see Xiamen Amoytop Biotech Co Ltd balance sheet assets.
Annual Working Capital to Net Assets for Xiamen Amoytop Biotech Co Ltd (2016–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for Xiamen Amoytop Biotech Co Ltd from 2016 to 2024, covering 9 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. Check asset resilience ratio of Xiamen Amoytop Biotech Co Ltd to evaluate the company's liquid asset resilience ratio.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 55.1% | CN¥1.41 Billion | CN¥2.55 Billion | CN¥1.83 Billion | CN¥420.63 Million | ▲ +5.2 pp |
| 2023 | 49.9% | CN¥936.53 Million | CN¥1.88 Billion | CN¥1.34 Billion | CN¥403.66 Million | ▲ +1.1 pp |
| 2022 | 48.9% | CN¥687.72 Million | CN¥1.41 Billion | CN¥955.61 Million | CN¥267.89 Million | ▼ -7.7 pp |
| 2021 | 56.6% | CN¥657.19 Million | CN¥1.16 Billion | CN¥834.42 Million | CN¥177.23 Million | ▼ -9.2 pp |
| 2020 | 65.8% | CN¥657.86 Million | CN¥1.00 Billion | CN¥772.80 Million | CN¥114.94 Million | ▲ +13.5 pp |
| 2019 | 52.3% | CN¥294.48 Million | CN¥563.55 Million | CN¥445.20 Million | CN¥150.72 Million | ▲ +3.4 pp |
| 2018 | 48.8% | CN¥243.81 Million | CN¥499.26 Million | CN¥373.85 Million | CN¥130.04 Million | ▲ +12.2 pp |
| 2017 | 36.6% | CN¥176.81 Million | CN¥483.26 Million | CN¥295.38 Million | CN¥118.57 Million | ▲ +1.1 pp |
| 2016 | 35.5% | CN¥169.66 Million | CN¥478.09 Million | CN¥301.80 Million | CN¥132.15 Million | — |